Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2020-04-17 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release update on COVID-19 compassionate use with a drug, but does not contain financial statements or detailed financial data. The document length is short (2141 characters) and it primarily serves as a regulatory update rather than a full financial report. According to the rules, Form 6-K filings are generally classified under Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit into other specific categories like Annual Report or Interim Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-04-17 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, RedHill Biopharma Ltd. It includes a press release update on a COVID-19 compassionate use program. The document length is 2145 characters, which is relatively short and primarily serves as an announcement of information rather than a detailed report. Form 6-K filings are typically used for current reports by foreign private issuers and often contain press releases or other material information updates. This document does not contain detailed financial statements or comprehensive analysis, nor does it represent an annual or quarterly report. It is not a certification or officer attestation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-04-13 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about the approval of compassionate use of a drug for COVID-19 in Italy. Form 6-K is a periodic report for foreign private issuers to disclose material information. The document is short (2058 characters) and primarily serves as a regulatory filing to announce a press release rather than a full financial report or detailed filing. It does not contain financial statements or detailed analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-04-06 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The content includes a press release about a COVID-19 patient treated under compassionate use, and it is a regulatory filing to update the market. The document length is 2073 characters, which is relatively short and does not contain detailed financial statements or substantive financial data. It is not an annual report, earnings release, or other detailed financial report. It is a regulatory announcement/report filed with the SEC. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-04-06 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by RedHill Biopharma Ltd., which is a report of a foreign private issuer pursuant to SEC rules. It includes information about an acquisition and an amendment to a credit agreement, along with exhibits such as the amendment and a press release. The document is 3546 characters long, which is relatively short and primarily serves as an announcement of these events rather than a detailed financial report. Form 6-K filings are typically used for current reports by foreign private issuers and often contain regulatory announcements or updates rather than full financial statements or detailed reports. Therefore, this document fits best under Regulatory Filings (RNS) as it does not contain comprehensive financial data or detailed management discussion but rather regulatory disclosure of corporate events and agreements.
2020-04-02 English
FORM 6-K
AGM Information Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, RedHill Biopharma Ltd. It contains a notice of the Annual General Meeting (AGM) of shareholders scheduled for May 4, 2020, and a detailed proxy statement related to that AGM. The content includes agenda items for the AGM such as election and re-election of directors, approval of auditor appointment, amendments to compensation policies, option grants, and share capital increase. It also provides instructions for shareholders on voting and proxy submission. The document does not contain financial statements or detailed financial performance data but rather materials related to the AGM and proxy solicitation. Therefore, it fits the category of AGM Information (AGM-R).
2020-04-01 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.